⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21574360 | 0.76 | NLRP3 (0.36) | — | |
| SCHEMBL17803593 | 0.71 | — | — | |
| SCHEMBL22529460 | 0.71 | — | — | |
| SCHEMBL28670667 | 0.67 | — | — | |
| SCHEMBL21801545 | 0.67 | — | — | |
| SCHEMBL14145170 | 0.66 | — | — | |
| SCHEMBL21798308 | 0.64 | — | — | |
| SCHEMBL18641449 | 0.64 | — | — | |
| SCHEMBL30009890 | 0.63 | JAK1 (0.34) | — | |
| SCHEMBL9017756 | 0.62 | NLRP3 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780852-B2 | Methods for treating Crohn's disease using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780852-B2 | Methods for treating Crohn's disease using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-20210179637-A1 | NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-06-17 | — | — | US | disclosed |
| US-10947254-B2 | Methods for treating ulcerative colitis using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200040010-A1 | NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-02-06 | — | — | US | disclosed |
| US-20170305934-A1 | NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170305934-A1 | NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-10-26 | — | — | US | disclosed |
| US-9725470-B2 | Substituted naphthyridines as JAK kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725470-B2 | Substituted naphthyridines as JAK kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160347772-A1 | NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160347772-A1 | NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-12-01 | — | — | US | disclosed |